healthcare

Plus, fund managers outline the key trends shaping the sector.

The healthcare sector is benefiting from rapid innovation, fuelled by a significant jump in COVID-led funding.

AI has enormous potential to improve healthcare delivery across the globe, and some practical applications could benefit investors.

With the healthcare sector in a deep and prolonged downturn, valuations of public and private R&D stage companies are very attractive.

Markets were more subdued in April after the strong start to the year. The S&P/ASX 200 Accumulation Index was down 2.9% and the S&P/ASX Small Ordinaries Accumulation...

Early-stage healthcare investment is not for the faint-hearted (or under-researched). No one could accuse Hashan De Silva of either.

Pulsed Field Ablation is the most exciting technology to come to market in many years, and offers great potential returns for the winners

Drug development pipelines are the lifeblood of the pharmaceutical industry. It is crucial for investors to understand milestones like FDA approvals and the impact of...

Telix Pharmaceuticals has just reported its first year of positive operating cashflow... helping it to achieve NPAT.

The rapid pace of change in biotechnology is creating a golden age of innovation - and three experts share what they are watching.

CSL has delivered bumper returns once again in its half-year report but suffered a major setback this week.

There are two parts of the market we believe are setting up for strong returns in 2024: Small caps and Healthcare.

The medtech landscape is rife with fast growing companies typically operating in oligopolistic industry structures that drive profitability.

The collapse of China chatter seems overcooked. The China A-share market now looks like a screaming buy, so I list my Crazy-Eight top picks.

Below is a summary of the topics we covered on Nucleus Investment Insights this month. See the links for more information.

In this interview, KKR's Richard Schoenfeld outlines where he is seeing stress in the market today.

Morningstar has released its Q4 2023 guide to undervalued stocks and there’s a few big hitters in the mix.

Miracle weight loss drugs are providing opportunity in the Healthcare sector, and its not Novo-Nordisk

Having taken a defensive view to date, the investment bank is now pulling in more risk and argues we’re in an expansionary phase.

Quality is one of the key factors for blue chip company status, but our definitions change. Here's what to look for in future blue chips.